Please assess the completion status of the following clinical trial:

Trial Title: A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed as Ph+ ALL who are either relapsed after or refractory to standard therapy~* Diagnosed as CML in blast crisis or accelerated phase or chronic phase who are resistant or intolerant to imatinib~* Performance status is normal or ambulatory and capable of all self-care Exclusion Criteria~* A history of significant or serious uncontrolled cardiovascular disease~* Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of nilotinib~* Patients who are pregnant or breast feeding, or adults of reproductive potential not employing an effective method of birth control~Exclusion Criteria:~* Cytopathologically confirmed CNS infiltration NB: in absence of suspicion of CNS involvement, lumbar puncture is not required~* Impaired cardiac function, including any one of the following~  * LVEF \< 45% as determined by echocardiogram~ * Complete left bundle branch block~ * Use of a cardiac pacemaker~ * ST depression of \> 1mm in 2 or more leads and/or T-wave inversions in 2 or more contiguous leads~ * Congenital long QT syndrome~ * History of or presence of significant ventricular or atrial tachyarrhythmias~ * Clinically significant resting bradycardia (\< 50 beats per minute)~ * QTc \> 480 msec on screening ECG (using the QTcF formula)~ * Right bundle branch block plus left anterior hemiblock, bifascicular block~ * Myocardial infarction within 3 months prior to starting AMN107~ * Uncontrolled angina pectoris~* Other clinically significant heart disease (e.g., congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)~* Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of AMN107 (e.g. ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)~* Use of therapeutic warfarin~* Acute or chronic liver or renal disease considered unrelated to tumor (e.g., hepatitis, cirrhosis, renal insufficiency, etc.)~* Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled diabetes, active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol~* Treatment with any hematopoietic colony-stimulating growth factors (e.g., G-CSF) ≤ 1 week prior to starting study drug.~* Patients who are currently receiving treatment with any of the medications listed in (cf. Post-text suppl. 5) that cannot be either discontinued or switched to a different medication prior to starting study drug. The medications listed in (cf. Post-text suppl. 5) have the potential to prolong the Q-T interval.~* Patients who have received chemotherapy ≤ 1 week or who are within 5 half-lives of their last dose chemotherapy (6 weeks for nitrosurea or mitomycin-C) prior to starting study drug or who have not recovered from side effects of such therapy. Hydroxyurea is permitted at the investigator's discretion prior to enrollment.~* Patients who have received Glivec® ≤ 1 week or who have not recovered from side effects of such therapy.~* Patients who have received immunotherapy ≤ 1 week prior to starting study drug or who have not recovered from side effects of such therapy.~* Patients who have received any investigational drug (excluding STI571/Glivec) ≤ 4 weeks or investigational cytotoxic agent within 1 week (or who are within 5 half-lives of a previous investigational cytotoxic agent) prior to starting study drug or who have not recovered from side effects of such therapy.~* Patients who have received wide field radiotherapy ≤ 4 week or limited field radiation for palliation ≤ 2 week prior to starting study drug or who have not recovered from side effects of such therapy.~* Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy.~* Patients who are pregnant or breast feeding, or adults of reproductive potential not employing an effective method of birth control. (Women of childbearing potential must have a negative serum pregnancy test within 48 hrs prior to administration of AMN107). Post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female patients must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug~* Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory)~* Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention.~* Patients unwilling or unable to comply with the protocol~Other protocol-defined inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nilotinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).